KOREA WHO
-
-
-
Chairman of Pharmicell
Kim Hyun-soo
Doctor-Turned-Entrepreneur Develops World's First Stem Cell Therapy, Focuses on Expanding Production Capacity
-
Last Updated on Feb 11, 2025
-
Chairman of Pharmicell
Life Summary
Kim Hyun-soo is the Chairman and CEO of Pharmicell. He also serves as the Chief Director of 'Kim Hyun-soo Stem Cell Clinic.'
He is focusing on expanding the production capacity of stem cell therapeutics.
He was born in January 1964 in Seoul.
He graduated from Yonsei University Wonju College of Medicine and earned a master's degree from Ajou University School of Medicine.
He worked as an assistant professor in the Hematology-Oncology Department at Ajou University before founding the stem cell therapy venture company FCB-Pharmicell in 2002.
He acquired a clothing company to list FCB-Pharmicell through a backdoor listing and later acquired IDBchem to enter the gene therapy raw material business.
He developed the world's first stem cell therapy.
He is committed to the research, development, and commercialization of nucleosides, a raw material for gene therapy.
#KimHyunsoo #Pharmicell #stemcell #biotechnology #genetherapy #medicalresearch #healthcare #biopharma #biotechstartup #nucleosides
He is focusing on expanding the production capacity of stem cell therapeutics.
He was born in January 1964 in Seoul.
He graduated from Yonsei University Wonju College of Medicine and earned a master's degree from Ajou University School of Medicine.
He worked as an assistant professor in the Hematology-Oncology Department at Ajou University before founding the stem cell therapy venture company FCB-Pharmicell in 2002.
He acquired a clothing company to list FCB-Pharmicell through a backdoor listing and later acquired IDBchem to enter the gene therapy raw material business.
He developed the world's first stem cell therapy.
He is committed to the research, development, and commercialization of nucleosides, a raw material for gene therapy.
#KimHyunsoo #Pharmicell #stemcell #biotechnology #genetherapy #medicalresearch #healthcare #biopharma #biotechstartup #nucleosides